# Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

> **NCT05724693** · PHASE1 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Healthy Volunteer
- Hepatic Impairment

## Interventions

- **DRUG:** Bemnifosbuvir (BEM)

## Key facts

- **NCT ID:** NCT05724693
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-30
- **Primary completion:** 2024-04-23
- **Final completion:** 2024-04-23
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05724693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05724693, "Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05724693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*